

# Review of: "Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series"

Atara Ntekim

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

The authors did not discuss the limitations of their study

Discussion should also take into account the current treatment for Her 2 +ve breast cancer which includes pertuzumab and T-DMI. In addition the PARP inhibitors have also been introduced in to the treatment of some breast cancer. These may alter the overall survival of these patients. To make the work to be of current relevance, the authors should discuss current data on these later treatment choices with their work.